Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators

Andreas Ritzén; Jesper Mosolff Mathiesen; Christian Thomsen

doi:10.1111/j.1742-7843.2005.pto_156.x

Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators

Andreas Ritzén, Jesper Mosolff Mathiesen, Christian Thomsen^*

^*Corresponding author for this work

Faculty of Law

90 Citations (Scopus)

Abstract

The metabotropic glutamate receptors (mGluR) consist of a family of eight G-protein-coupled receptors that differ in their function, distribution and physiological roles within the central nervous system. In recent years substantial efforts have been made towards developing selective agonists and antagonists which have proven useful for elucidating their potential as novel targets for the treatment of psychiatric and neurological diseases. In the present review we will provide an update of the recent developments of functional allosteric modulators of the mGluR family and explore their therapeutic potential for anxiety/depression, schizophrenia, epilepsy/stroke, pain and Alzheimer's, Parkinson's and Huntington's diseases.

Original language	English
Journal	Basic and Clinical Pharmacology and Toxicology
Volume	97
Issue number	4
Pages (from-to)	202-213
Number of pages	12
ISSN	1742-7835
DOIs	https://doi.org/10.1111/j.1742-7843.2005.pto_156.x
Publication status	Published - 1 Oct 2005

Access to Document

10.1111/j.1742-7843.2005.pto_156.x

Cite this

@misc{9d4da19609c6466cab97f6e8c0c67c18,

title = "Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators",

abstract = "The metabotropic glutamate receptors (mGluR) consist of a family of eight G-protein-coupled receptors that differ in their function, distribution and physiological roles within the central nervous system. In recent years substantial efforts have been made towards developing selective agonists and antagonists which have proven useful for elucidating their potential as novel targets for the treatment of psychiatric and neurological diseases. In the present review we will provide an update of the recent developments of functional allosteric modulators of the mGluR family and explore their therapeutic potential for anxiety/depression, schizophrenia, epilepsy/stroke, pain and Alzheimer's, Parkinson's and Huntington's diseases.",

author = "Andreas Ritz{\'e}n and Mathiesen, {Jesper Mosolff} and Christian Thomsen",

year = "2005",

month = oct,

day = "1",

doi = "10.1111/j.1742-7843.2005.pto_156.x",

language = "English",

volume = "97",

pages = "202--213",

journal = "Basic and Clinical Pharmacology and Toxicology",

issn = "1742-7835",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - GEN

T1 - Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators

AU - Ritzén, Andreas

AU - Mathiesen, Jesper Mosolff

AU - Thomsen, Christian

PY - 2005/10/1

Y1 - 2005/10/1

N2 - The metabotropic glutamate receptors (mGluR) consist of a family of eight G-protein-coupled receptors that differ in their function, distribution and physiological roles within the central nervous system. In recent years substantial efforts have been made towards developing selective agonists and antagonists which have proven useful for elucidating their potential as novel targets for the treatment of psychiatric and neurological diseases. In the present review we will provide an update of the recent developments of functional allosteric modulators of the mGluR family and explore their therapeutic potential for anxiety/depression, schizophrenia, epilepsy/stroke, pain and Alzheimer's, Parkinson's and Huntington's diseases.

AB - The metabotropic glutamate receptors (mGluR) consist of a family of eight G-protein-coupled receptors that differ in their function, distribution and physiological roles within the central nervous system. In recent years substantial efforts have been made towards developing selective agonists and antagonists which have proven useful for elucidating their potential as novel targets for the treatment of psychiatric and neurological diseases. In the present review we will provide an update of the recent developments of functional allosteric modulators of the mGluR family and explore their therapeutic potential for anxiety/depression, schizophrenia, epilepsy/stroke, pain and Alzheimer's, Parkinson's and Huntington's diseases.

UR - http://www.scopus.com/inward/record.url?scp=26444616159&partnerID=8YFLogxK

U2 - 10.1111/j.1742-7843.2005.pto_156.x

DO - 10.1111/j.1742-7843.2005.pto_156.x

M3 - Short survey

C2 - 16176554

AN - SCOPUS:26444616159

SN - 1742-7835

VL - 97

SP - 202

EP - 213

JO - Basic and Clinical Pharmacology and Toxicology

JF - Basic and Clinical Pharmacology and Toxicology

IS - 4

ER -

Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators

Abstract

Access to Document

Other files and links

Fingerprint

Cite this